Gilead Sciences, Inc.NASDAQ: GILD

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

· Issued by Gilead Sciences, Inc. via Business Wire

Summary by 6ix AI

Gilead Sciences, Inc., a biopharmaceutical company, will release its third quarter 2026 financial results and guidance on Thursday, October 29, 2026 after the market closes.

Key details

  • Management will host a webcast at 4:30 p.m. Eastern Time on October 29, 2026 to discuss the third quarter 2026 results and give a business update.
  • The live webcast will be available in the Investors section of the Gilead website and archived there for one year.

6ix AI wrote this summary from the release below and checked it against the release.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2026 financial results and provide a business update.

A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View original source (Business Wire)Gilead Sciences, Inc. on 6ix

Story so far

Earlier from Gilead Sciences

Later from Gilead Sciences

All Gilead Sciences news releases